Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792641 | 0.86 | — | — | |
| SCHEMBL287199 | 0.86 | — | — | |
| SCHEMBL191463 | 0.86 | SMN1; SMN2 (0.50) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL8237311 | 0.85 | TEAD4 (0.44) | MEN1ALDH1A1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL1415431 | 0.85 | SCN9A (0.50) | LTA4HMEN1KMT2AL3MBTL1 | |
| SCHEMBL30864880 | 0.83 | GRM5 (0.48) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL27314075 | 0.83 | GRM5 (0.48) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL1415877 | 0.82 | FGFR2 (0.42) | FGFR2 | |
| SCHEMBL30864838 | 0.82 | TGFBR1 (0.40) | CCR1CCR5CCR8MEN1ALDH1A1 | |
| SCHEMBL27314344 | 0.82 | TGFBR1 (0.40) | CCR1CCR5CCR8MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986645-B1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| EP-1490360-B1 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2011-03-16 | — | — | EP | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-1986645-A1 | GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007089512-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| EP-1490360-A4 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2006-07-05 | — | — | EP | disclosed |
| EP-1490360-A1 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2004-12-29 | — | — | EP | disclosed |
| US-6787551-B2 | ORAL ADMINISTRATION; TREATING INSULIN RESISTANCE USING A NEW MECHANISM TO LOWER BLOOD SUGAR LEVEL BY INCREASING PHYSIOLOG-ICAL EFFECTS OF INSULIN ON TARGET CELLS (MUSCLE, ADIPOCYTES, LIVER); ALSO STRONGER ANTILIPIDEMIC THAN ROSIGLITAZONE | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2004-09-07 | — | — | US | disclosed |
| US-20040122031-A1 | Thiazolidinedione and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2004-06-24 | — | — | US | disclosed |
| WO-2003080605-A1 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | CCR1 4736/4885CCR5 4586/4885CCR8 4767/4885 |
| US-20040122031-A1 | Thiazolidinedione and pharmaceutical composition comprising the same | GLP1R, PPARD, SLC5A1 | CCR1 949/4885CCR5 1000/4885CCR8 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.